Annexon, Inc.

NasdaqGS:ANNX Voorraadrapport

Marktkapitalisatie: US$547.9m

Annexon Beheer

Beheer criteriumcontroles 4/4

De CEO Annexon is Doug Love, benoemd in Dec2014, heeft een ambtstermijn van 9.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.45M, bestaande uit 24.2% salaris en 75.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.28% van de aandelen van het bedrijf, ter waarde $ 1.53M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.5 jaar en 6.1 jaar.

Belangrijke informatie

Doug Love

Algemeen directeur

US$2.5m

Totale compensatie

Percentage CEO-salaris24.2%
Dienstverband CEO9.9yrs
Eigendom CEO0.3%
Management gemiddelde ambtstermijn2.5yrs
Gemiddelde ambtstermijn bestuur6.1yrs

Recente managementupdates

Recent updates

We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely

Sep 27
We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely

Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS

Aug 17

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Jun 04

Annexon: Unforced Error Sullies Prospects

Apr 03

Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation

Nov 10
Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Jul 25
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Apr 11
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Are Investors Undervaluing Annexon, Inc. (NASDAQ:ANNX) By 25%?

Feb 14
Are Investors Undervaluing Annexon, Inc. (NASDAQ:ANNX) By 25%?

We Think Annexon (NASDAQ:ANNX) Needs To Drive Business Growth Carefully

Dec 28
We Think Annexon (NASDAQ:ANNX) Needs To Drive Business Growth Carefully

Annexon started as a buy at Jefferies on market potential of candidates, data catalysts

Sep 16

Annexon: A First Take

Aug 21

Annexon Biosciences GAAP EPS of -$0.96 misses by $0.02

Aug 08

Annexon to raise $130M in stock and warrant offering

Jul 08

We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate

Apr 16
We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Jan 01
Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Sep 08
Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

May 22
We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

Feb 06
We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

Dosing underway in Annexon's Phase 2/3 study of monoclonal antibody in Guillain-Barré Syndrome

Dec 21

Annexon Biosciences EPS misses by $0.43

Nov 16

Analyse CEO-vergoeding

Hoe is Doug Love's beloning veranderd ten opzichte van Annexon's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$118m

Jun 30 2024n/an/a

-US$115m

Mar 31 2024n/an/a

-US$121m

Dec 31 2023US$2mUS$593k

-US$134m

Sep 30 2023n/an/a

-US$141m

Jun 30 2023n/an/a

-US$143m

Mar 31 2023n/an/a

-US$145m

Dec 31 2022US$4mUS$569k

-US$142m

Sep 30 2022n/an/a

-US$145m

Jun 30 2022n/an/a

-US$145m

Mar 31 2022n/an/a

-US$140m

Dec 31 2021US$8mUS$534k

-US$130m

Sep 30 2021n/an/a

-US$116m

Jun 30 2021n/an/a

-US$103m

Mar 31 2021n/an/a

-US$84m

Dec 31 2020US$5mUS$446k

-US$70m

Sep 30 2020n/an/a

-US$56m

Jun 30 2020n/an/a

-US$45m

Mar 31 2020n/an/a

-US$42m

Dec 31 2019US$3mUS$396k

-US$38m

Sep 30 2019n/an/a

-US$34m

Jun 30 2019n/an/a

-US$28m

Mar 31 2019n/an/a

-US$23m

Dec 31 2018US$518kUS$379k

-US$18m

Compensatie versus markt: De totale vergoeding ($USD 2.45M ) Doug } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.14M ).

Compensatie versus inkomsten: De vergoeding van Doug is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.


CEO

Doug Love (56 yo)

9.9yrs

Tenure

US$2,453,184

Compensatie

Mr. Douglas Love, Esq., J.D, also known as Doug, has been the President, Director and Chief Executive Officer of Annexon Inc. since December 2014. He has extensive business and legal leadership experience...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Douglas Love
CEO, President & Director9.9yrsUS$2.45m0.28%
$ 1.5m
Dean Artis
Chief Scientific Officer & Executive VP1.8yrsUS$1.83m0.047%
$ 258.7k
Ted Yednock
Executive VP3.1yrsUS$1.14m0.067%
$ 366.8k
Jennifer Lew
Executive VP5.4yrsUS$1.44m0.026%
$ 141.5k
Michael Overdorf
Executive VP & Chief Business Officer4.3yrsUS$1.40m0.033%
$ 183.4k
Henk-Andre Kroon
Senior Vice President of Translational Medicineno datageen gegevensgeen gegevens
Jamie Dananberg
Executive VP & Chief Medical Officer1.3yrsgeen gegevensgeen gegevens
Shikhar Agarwal
Senior VP & Head of Commercialless than a yeargeen gegevensgeen gegevens
Sunil Mehta
Senior VP of Medical Affairsless than a yeargeen gegevensgeen gegevens

2.5yrs

Gemiddelde duur

59.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ANNX wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.5 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Douglas Love
CEO, President & Director9.9yrsUS$2.45m0.28%
$ 1.5m
Ted Yednock
Executive VPless than a yearUS$1.14m0.067%
$ 366.8k
Muneer Satter
Independent Director9.9yrsUS$103.93k0.76%
$ 4.1m
Thomas Wiggans
Independent Chairman7.8yrsUS$132.43k0.00025%
$ 1.4k
Jung Choi
Independent Director4.4yrsUS$100.93k0%
$ 0
William Waddill
Independent Director3.3yrsUS$103.43k0%
$ 0
Thomas Maniatis
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
David Holtzman
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Stephen Hauser
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Jeffrey Goldberg
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
P. Willison
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Beth Stevens
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens

6.1yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ANNX wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.1 jaar).